Synthesis and Characterization of Impurities in Rasagiline: A Novel MAO-B Inhibitor in Parkinson’s Disease Therapy

Abstract

Rasagiline (1) is indicated as adjunctive therapy and monotherapy for treatment of Parkinson's disease approved by the FDA. During the process development of rasagiline, few processes related impurities were observed along with the final API. These impurities were identified as indanol (2), indanamine (3), allyl (4), keto (7), other isomer (6) and chloro allyl (5,5a) impurities. The present work describes the synthesis of all these impurities and characterized by 1 H NMR and Mass spectral analysis.